PDF herunterladen
Semin Thromb Hemost 2009; 35(5): 497-504
DOI: 10.1055/s-0029-1234145
© Thieme Medical Publishers

Systolic Heart Failure: A Prothrombotic State

Olav R. de Peuter1 , Wouter E. M Kok2 , Christian Torp-Pedersen3 , Harry R. Büller1 , Pieter W. Kamphuisen1
  • 1Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
  • 2Department of Cardiology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
  • 3Department of Cardiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
08. September 2009 (online)

    Lizenzen und Reprints

ABSTRACT

Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as β-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic state in heart failure. This article focuses on this prothrombotic state and discusses the risk of thromboembolic events, pathophysiological mechanisms, and the potential role of anticoagulant treatment.

KEYWORDS

Heart failure - hemostasis - anticoagulants - platelet aggregation inhibitors

REFERENCES

  • 1 McMurray J J, Petrie M C, Murdoch D R, Davie A P. Clinical epidemiology of heart failure: public and private health burden.  Eur Heart J. 1998;  19(suppl P) P9-P16
    PubMedGoogle Scholar
  • 2 Davis R C, Hobbs F D, Lip G Y. ABC of heart failure. History and epidemiology.  BMJ. 2000;  320(7226) 39-42
    CrossrefPubMedGoogle Scholar
  • 3 Lip G Y, Chung I. Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review.  QJM. 2002;  95(7) 451-459
    CrossrefPubMedGoogle Scholar
  • 4 Lip G Y, Chung I. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review.  QJM. 2002;  95(7) 461-468
    CrossrefPubMedGoogle Scholar
  • 5 The CONSENSUS Trial Study Group . Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).  N Engl J Med. 1987;  316(23) 1429-1435
    CrossrefPubMedGoogle Scholar
  • 6 Køber L, Torp-Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study.  Am J Cardiol. 1995;  76(1) 1-5
    CrossrefPubMedGoogle Scholar
  • 7 McMurray J, McDonagh T, Morrison C E, Dargie H J. Trends in hospitalization for heart failure in Scotland 1980–1990.  Eur Heart J. 1993;  14(9) 1158-1162
    PubMedGoogle Scholar
  • 8 Cleland J G, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving?.  Eur J Heart Fail. 1999;  1(3) 229-241
    CrossrefPubMedGoogle Scholar
  • 9 Mosterd A, Hoes A W. Clinical epidemiology of heart failure.  Heart. 2007;  93(9) 1137-1146
    CrossrefPubMedGoogle Scholar
  • 10 Chung I, Lip G Y. Antithrombotic therapy for congestive heart failure.  Int J Clin Pract. 2006;  60(1) 36-47
    CrossrefPubMedGoogle Scholar
  • 11 Pullicino P, Thompson J L, Barton B, Levin B, Graham S, Freudenberger R S. WARCEF Investigators . Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design.  J Card Fail. 2006;  12(1) 39-46
    CrossrefPubMedGoogle Scholar
  • 12 Witt B J, Gami A S, Ballman K V et al.. The incidence of ischemic stroke in chronic heart failure: a meta-analysis.  J Card Fail. 2007;  13(6) 489-496
    CrossrefPubMedGoogle Scholar
  • 13 Fox K, Ford I, Steg P G, Tendera M, Ferrari R. BEAUTIFUL Investigators . Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.  Lancet. 2008;  372(9641) 807-816
    CrossrefPubMedGoogle Scholar
  • 14 Orn S, Cleland J G, Romo M, Kjekshus J, Dickstein K. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction.  Am J Med. 2005;  118(7) 752-758
    CrossrefPubMedGoogle Scholar
  • 15 Uretsky B F, Thygesen K, Armstrong P W et al.. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial.  Circulation. 2000;  102(6) 611-616
    PubMedGoogle Scholar
  • 16 Beemath A, Stein P D, Skaf E, Al Sibae M R, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure.  Am J Cardiol. 2006;  98(6) 793-795
    CrossrefPubMedGoogle Scholar
  • 17 Howell M D, Geraci J M, Knowlton A A. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study.  J Clin Epidemiol. 2001;  54(8) 810-816
    CrossrefPubMedGoogle Scholar
  • 18 Cokkinos D V, Haralabopoulos G C, Kostis J B, Toutouzas P K. HELAS investigators . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study.  Eur J Heart Fail. 2006;  8(4) 428-432
    CrossrefPubMedGoogle Scholar
  • 19 Freudenberger R S, Hellkamp A S, Halperin J L SCD-HeFT Investigators et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).  Circulation. 2007;  115(20) 2637-2641
    CrossrefPubMedGoogle Scholar
  • 20 Loh E, Sutton M S, Wun C C et al.. Ventricular dysfunction and the risk of stroke after myocardial infarction.  N Engl J Med. 1997;  336(4) 251-257
    CrossrefPubMedGoogle Scholar
  • 21 Dries D L, Rosenberg Y D, Waclawiw M A, Domanski M J. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials.  J Am Coll Cardiol. 1997;  29(5) 1074-1080
    CrossrefPubMedGoogle Scholar
  • 22 Gibbs C R, Blann A D, Watson R D, Lip G Y. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.  Circulation. 2001;  103(13) 1746-1751
    PubMedGoogle Scholar
  • 23 Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley C M, Cleland J G. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure.  Am Heart J. 1994;  127(3) 607-612
    CrossrefPubMedGoogle Scholar
  • 24 Lip G Y, Gibbs C R. Does heart failure confer a hypercoagulable state? Virchow’s triad revisited.  J Am Coll Cardiol. 1999;  33(5) 1424-1426
    CrossrefPubMedGoogle Scholar
  • 25 Niebauer J, Volk H D, Kemp M et al.. Endotoxin and immune activation in chronic heart failure: a prospective cohort study.  Lancet. 1999;  353(9167) 1838-1842
    CrossrefPubMedGoogle Scholar
  • 26 Felmeden D C, Lip G Y. The renin-angiotensin-aldosterone system and fibrinolysis.  J Renin Angiotensin Aldosterone Syst. 2000;  1(3) 240-244
    CrossrefPubMedGoogle Scholar
  • 27 Vaughan D E. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition.  Clin Cardiol. 1997;  20(11 suppl 2) II-34-II-37
    PubMedGoogle Scholar
  • 28 Gavras H, Lever A F, Brown J J, Macadam R F, Robertson J I. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II.  Lancet. 1971;  2(7714) 19-22
    PubMedGoogle Scholar
  • 29 Goodfield N E, Newby D E, Ludlam C A, Flapan A D. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.  Circulation. 1999;  99(23) 2983-2985
    PubMedGoogle Scholar
  • 30 Usalan C, Buyukhatipoglu H. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.  Clin Appl Thromb Hemost. 2008;  14(2) 203-209
    CrossrefPubMedGoogle Scholar
  • 31 Køber L, Torp-Pedersen C, Carlsen J E Trandolapril Cardiac Evaluation (TRACE) Study Group et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.  N Engl J Med. 1995;  333(25) 1670-1676
    CrossrefPubMedGoogle Scholar
  • 32 Yusuf S, Pepine C J, Garces C et al.. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.  Lancet. 1992;  340(8829) 1173-1178
    CrossrefPubMedGoogle Scholar
  • 33 Azevedo E R, Kubo T, Mak S et al.. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.  Circulation. 2001;  104(18) 2194-2199
    CrossrefPubMedGoogle Scholar
  • 34 von Känel R, Dimsdale J E. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo.  Eur J Haematol. 2000;  65(6) 357-369
    CrossrefPubMedGoogle Scholar
  • 35 Grignani G, Pacchiarini L, Zucchella M et al.. Effect of mental stress on platelet function in normal subjects and in patients with coronary artery disease.  Haemostasis. 1992;  22(3) 138-146
    PubMedGoogle Scholar
  • 36 Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance.  Eur J Clin Invest. 1996;  26(5) 353-370
    CrossrefPubMedGoogle Scholar
  • 37 Packer M, Coats A J, Fowler M B Carvedilol Prospective Randomized Cumulative Survival Study Group et al. Effect of carvedilol on survival in severe chronic heart failure.  N Engl J Med. 2001;  344(22) 1651-1658
    CrossrefPubMedGoogle Scholar
  • 38 CIBIS-II Investigators and Committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.  Lancet. 1999;  353(9146) 9-13
    CrossrefPubMedGoogle Scholar
  • 39 Torp-Pedersen C, Poole-Wilson P A, Swedberg K COMET Investigators et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET.  Am Heart J. 2005;  149(2) 370-376
    CrossrefPubMedGoogle Scholar
  • 40 Kohno T, Yoshikawa T, Yoshizawa A et al.. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure.  Cardiovasc Drugs Ther. 2005;  19(5) 347-355
    CrossrefPubMedGoogle Scholar
  • 41 Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis.  BMJ. 1999;  318(7200) 1730-1737
    PubMedGoogle Scholar
  • 42 Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J P. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials.  Circulation. 1998;  98(12) 1184-1191
    PubMedGoogle Scholar
  • 43 Zee R Y, Cook N R, Cheng S, Erlich H A, Lindpaintner K, Ridker P M. Polymorphism in the beta2-adrenergic receptor and lipoprotein lipase genes as risk determinants for idiopathic venous thromboembolism: a multilocus, population-based, prospective genetic analysis.  Circulation. 2006;  113(18) 2193-2200
    CrossrefPubMedGoogle Scholar
  • 44 O’Donnell J, Manning R A, Laffan M A. Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis.  Br J Haematol. 2003;  123(1) 139-141
    CrossrefPubMedGoogle Scholar
  • 45 Nossent A Y, Dai L, Rosendaal F R, Vos H L, Eikenboom J C. Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis.  J Thromb Haemost. 2005;  3(2) 405-407
    CrossrefPubMedGoogle Scholar
  • 46 Lanfear D E, Jones P G, Marsh S, Cresci S, McLeod H L, Spertus J A. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.  JAMA. 2005;  294(12) 1526-1533
    CrossrefPubMedGoogle Scholar
  • 47 Dries D L, Domanski M J, Waclawiw M A, Gersh B J. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure.  Am J Cardiol. 1997;  79(7) 909-913
    CrossrefPubMedGoogle Scholar
  • 48 Al-Khadra A S, Salem D N, Rand W M, Udelson J E, Smith J J, Konstam M A. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction.  J Am Coll Cardiol. 1998;  31(4) 749-753
    CrossrefPubMedGoogle Scholar
  • 49 Al-Khadra A S, Salem D N, Rand W M, Udelson J E, Smith J J, Konstam M A. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.  J Am Coll Cardiol. 1998;  31(2) 419-425
    PubMedGoogle Scholar
  • 50 de Boer R A, Hillege H L, Tjeerdsma G, Verheugt F W, van Veldhuisen D J. Both antiplatelet and anticoagulant therapy may favorably affect outcome in patients with advanced heart failure. A retrospective analysis of the PRIME-II trial.  Thromb Res. 2005;  116(4) 279-285
    CrossrefPubMedGoogle Scholar
  • 51 Cleland J G, Findlay I, Jafri S et al.. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.  Am Heart J. 2004;  148(1) 157-164
    CrossrefPubMedGoogle Scholar
  • 52 Anderson G M, Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure.  Am Heart J. 1950;  39(5) 697-702
    CrossrefPubMedGoogle Scholar
  • 53 Griffith G C, Stragnell R, Levinson D C, Moore F J, Ware A G. A study of the beneficial effects of anticoagulant therapy in congestive heart failure.  Ann Intern Med. 1952;  37(5) 867-887
    PubMedGoogle Scholar
  • 54 Harvey W P, Finch C A. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure.  N Engl J Med. 1950;  242(6) 208-211
    CrossrefPubMedGoogle Scholar
  • 55 Lip G Y, Gibbs C R. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm.  Cochrane Database Syst Rev. 2001;  (4) CD003333
    PubMedGoogle Scholar
  • 56 Cleland J G, Bulpitt C J, Falk R H et al.. Is aspirin safe for patients with heart failure?.  Br Heart J. 1995;  74(3) 215-219
    CrossrefPubMedGoogle Scholar
  • 57 Teo K K, Yusuf S, Pfeffer M ACE Inhibitors Collaborative Group et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.  Lancet. 2002;  360(9339) 1037-1043
    CrossrefPubMedGoogle Scholar

O.R. de PeuterM.D. 

Academic Medical Centre, Department of Vascular Medicine

PO Box 22660, 1100 DD Amsterdam

eMail: O.R.dePeuter@amc.uva.nl